Antioxidants · 2023 · 24 citations · 50 references
MedicineMolecular BiologyMolecular GeneticsGene ExpressionGenome EditingRenal PathophysiologyDiabetes MellitusDiabetic Kidney DiseaseDiabetic NephropathyRenal DiseaseRenal Endocrine DysfunctionRenal Molecular PhysiologyCrispr-cas9 Genome EditingCrispr-cas9 KnockoutDiabetic Kidney Disease ProgressionLipid AccumulationNrf2 Signaling PathwayNuclear Factor Erythroid 2-Related Factor 2 SignalingProximal Tubular DysfunctionSodium-glucose Cotransport
The role(s) of nuclear factor erythroid 2-related factor 2 (NRF2) in diabetic kidney disease (DKD) is/are controversial. We hypothesized that Nrf2 deficiency in type 2 diabetes (T2D) db/db mice (db/dbNrf2 knockout (KO)) attenuates DKD progression through the down-regulation of angiotensinogen (AGT), sodium-glucose cotransporter-2 (SGLT2), scavenger receptor CD36, and fatty -acid-binding protein 4 (FABP4), and lipid accumulation in renal proximal tubular cells (RPTCs). Db/dbNrf2 KO mice were studied at 16 weeks of age. Human RPTCs (HK2) with NRF2 KO via CRISPR-Cas9 genome editing and kidneys from patients with or without T2D were examined. Compared with db/db mice, db/dbNrf2 KO mice had lower systolic blood pressure, fasting blood glucose, kidney hypertrophy, glomerular filtration rate, urinary albumin/creatinine ratio, tubular lipid droplet accumulation, and decreased expression of AGT, SGLT2, CD36, and FABP4 in RPTCs. Male and female mice had similar results. NRF2 KO attenuated the stimulatory effect of the Nrf2 activator, oltipraz, on AGT, SGLT2, and CD36 expression and high-glucose/free fatty acid (FFA)-stimulated lipid accumulation in HK2. Kidneys from T2D patients exhibited markedly higher levels of CD36 and FABP4 in RPTCs than kidneys from non-diabetic patients. These data suggest that NRF2 exacerbates DKD through the stimulation of AGT, SGLT2, CD36, and FABP4 expression and lipid accumulation in RPTCs of T2D.
50
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic, Meg Jardine, Bruce Neal et al. · New England Journal of Medicine · 2019 · 6K citations · Full text
Medicine, Nephrology, Pharmacology +17
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa‐Rotter et al. · New England Journal of Medicine · 2020 · 5.2K citations · Full text
Ken Itoh, Tomoki Chiba, Satoru Takahashi et al. · Biochemical and Biophysical Research Communications · 1997 · 4K citations
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner, Silvio E. Inzucchi, John M. Lachin et al. · New England Journal of Medicine · 2016 · 3.6K citations · Full text